MRI Anatomy of Schizophrenia

精神分裂症的 MRI 解剖

• 批准号: 8195955
• 负责人: Robert W McCarley
• 金额: --
• 依托单位: VA BOSTON HEALTH CARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-10-01 至 2014-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8195955
• 关键词: Accounting; Adolescent; Affect; Age; Anatomy; Antipsychotic Agents; Area; Auditory; Award; Brain; Brain Diseases; Brain Pathology; Brain region; Budgets; Caring; Cell Nucleus; Cerebrospinal Fluid; Chronic; Chronic Schizophrenia; Clinical; Communities; Complement; Data; Defect; Development; Diagnostic; Disease; Dose; Evaluation; Event-Related Potentials; Female; Gender; General Population; Generations; Gold; Grant; Handedness; Health; Health Care Costs; Hospitalization; Hospitals; Intervention Trial; Investigation; Knowledge; Language; Lead; Link; Liquid substance; Literature; Lithium; Lobe; Longitudinal Studies; MRI Scans; Magnetic Resonance Imaging; Manuals; Measures; Methods; Modeling; Mood stabilizers; Morbidity - disease rate; N-Methylaspartate; Neurobiology; Onset of illness; Outcome; Parental Ages; Patients; Pharmaceutical Preparations; Pharmacological Treatment; Physicians; Predictive Value; Process; Protocols documentation; Psychiatrist; Publications; Recruitment Activity; Recurrence; Reporting; Research; Research Methodology; Research Personnel; Role; Sampling; Scanning; Schizophrenia; Signs and Symptoms; Socioeconomic Status; Source; Subgroup; Superior temporal gyrus; Symptoms; Techniques; Temporal Lobe; Testing; Therapeutic; Time; Valproic Acid; Ventricular; Veterans; Work; age group; base; cingulate gyrus; compliance behavior; design; dosage; first episode schizophrenia; follow-up; frontal lobe; gamma-Aminobutyric Acid; gray matter; indexing; interest; lateral ventricle; male; neocortical; neural circuit; neurophysiology; neuropsychological; neurotransmission; non-compliance; prospective; protective effect; psychosocial; public health relevance; research clinical testing; severe mental illness; white matter; white matter change

DESCRIPTION (provided by applicant): Background: For many years the serious mental illness of schizophrenia was thought of as the consequence of abnormalities in development which emerged in the course of adolescent brain development, but whose brain abnormalities did not change after onset. Now, however a new paradigm of post-onset progression of loss of brain gray matter and concomitant increase of brain fluid spaces (CSF) visible on structural MRI scans has become a hot topic in schizophrenia research. As well as other studies, our current Merit award-sponsored longitudinal MRI study and its 68 publications provide strong preliminary evidence of progression. Still, many questions remain. Not all investigators agree on progression of gray matter loss as a part of schizophrenia, and the role of treatment medication in progressive brain changes is controversial. Research Methods: To answer key questions about progression, we propose a 5 year longitudinal naturalistic study in two groups, first episode schizophrenia (FESZ) and chronic schizophrenia (CSZ), both compared with equal numbers of healthy controls (HC) matched on age, gender and parental socio- economic status who will have the same longitudinal protocol; all subjects will have 3T MRI scans. FESZ will have MRIs and clinical/diagnostic evaluations: at 1) onset, objectively defined as first hospitalization (N=110 total over 5 years); 2) 6 months after initial scan (N=63 total); 3) 12 months after initial scan (N=40 total); and 4) 30 months after initial scan (N=20 total). The FESZ subject numbers at each time point reflect both our documented follow-up return rate and the duration constraints of a 5 year study and are based on 22 new FESZ entering each year of the study. We will use the gold standard of manual Region of Interest analysis of MRI scans together with clinical symptom/sign measures to provide answers to key questions. To facilitate comparison FESZ and CSZ will receive the same initial and follow-up clinical and neuropsychological evaluations. Medication status will be tracked monthly by the treating physician and compliance, dosage and load will be tracked for association with MRI/clinical changes. An important feature of this naturalistic study is that power calculations based on preliminary data indicate the FESZ sample N will be large enough to permit subgrouping on the basis of medication, gender and other variables. We will use three measures of onset, the schizophrenia onset scale, medication onset and first hospitalization and will determine which provides the best measure of onset, based on predictive value for MRI changes. Hypotheses: We hypothesize, based on preliminary data, that post-onset progression is most rapid in FESZ in the first 6 months after onset, compared with 28 CSZ at initial and at 30 month follow-up. In FESZ we expect gray matter progressive loss in widespread neocortical areas, most intense in frontal and temporal lobe, and, within these lobes, most intense and rapid in particular brain regions linked to SZ functional abnormalities, such as, for example, in superior temporal gyrus language and auditory processing regions, where it will be associated with progression of clinical symptoms of disorganization and thought disorder. We expect antipsychotic medication to slow progression of both gray matter loss & clinical symptoms while mood stabilizers will slow gray matter progression but will have lesser effect on clinical symptoms. PUBLIC HEALTH RELEVANCE: Significance: Our preliminary findings of a rapid post-onset progression of MRI changes in FESZ, if confirmed by the proposed study, would alter our conceptualization of the disorder, and suggest the need for intensive pharmacologic and psychosocial intervention trials at disease onset. Moreover, our study will help define which pharmacological treatments protect against progression. In addition to this potential reformulation of our understanding of progressive brain pathology in schizophrenia, the work proposed will increase our knowledge about what areas of the brain are affected in schizophrenia, an important contribution in its own right. Relevance to Veterans Health: Schizophrenia affects 1% of the general population and is one of the major sources of suffering, morbidity and expense in the VA. In fact, the 100,000 patients treated with schizophrenia each year account for nearly 12% of VA healthcare costs. Increase in knowledge about the brain areas underlying schizophrenia will lead to improvement in treatment and care for afflicted veterans.

描述（由申请人提供）：